GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

 GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

Shots:

  • The REALITI-A study involves assessing of Nucala (100mg, SC) in 368 patients with severe eosinophilic asthma, being conducted in a routine care setting, compared to the prior 12mos.
  • The REALITI-A study results: annual reduction rate in exacerbations (69%); reduction in exacerbations requiring hospitalization/emergency room visits (77%); reduction in m-oral corticosteroid (OCS) dose 10 mg/day to 5mg/day with 34% of patients able to stop OCS completely, study is expected to be completed in 2021
  • Nucala is mAb targeting IL-5, prevent its binding to its receptor on the surface of eosinophils, reducing blood eosinophils without completely depleting them and is an approved therapy in the US, EU & 20+ countries as an add-on maintenance treatment for patients with SEA

Click here to­ read full press release/ article | Ref: GSK | Image: European Biotechnology

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post